Trexquant Investment LP Avadel Pharmaceuticals PLC Transaction History

Trexquant Investment LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $272,008 - $422,228	42,435 New	42,435 $388,000
Q1 2022 May 13, 2022	SELL	$5.46 - $8.29 $128,310 - $194,814	-23,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $172,490 - $262,730	23,500 New	23,500 $190,000
Q3 2018 Nov 09, 2018	SELL	$4.08 - $7.14 $44,223 - $77,390	-10,839 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$5.89 - $7.78 $203,599 - $268,931	-34,567 Reduced 76.13%	10,839 $66,000
Q1 2018 May 03, 2018	BUY	$6.76 - $11.7 $209,762 - $363,051	31,030 Added 215.85%	45,406 $331,000
Q4 2017 Feb 09, 2018	SELL	$8.03 - $11.25 $175,391 - $245,722	-21,842 Reduced 60.31%	14,376 $118,000
Q3 2017 Nov 09, 2017	BUY	$8.35 - $10.5 $302,420 - $380,289	36,218	36,218 $380,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.